News
XOMAP
24.97
0.00%
-0.00
Weekly Report: what happened at XOMAP last week (0622-0626)?
Weekly Report · 5d ago
Weekly Report: what happened at XOMAP last week (0615-0619)?
Weekly Report · 06/22 09:55
Weekly Report: what happened at XOMAP last week (0608-0612)?
Weekly Report · 06/15 09:56
XOMA Preferred Shares Series A declares $0.539 dividend
Seeking Alpha · 06/12 20:14
Ligand agrees to buy XOMA Royalty for USD 39 a share in cash
PUBT · 06/12 20:09
XOMA Royalty declares USD 0.54 Series A preferred dividend, USD 0.52 Series B payout
PUBT · 06/12 20:05
Weekly Report: what happened at XOMAP last week (0601-0605)?
Weekly Report · 06/08 09:53
Weekly Report: what happened at XOMAP last week (0525-0529)?
Weekly Report · 06/01 09:56
Saying Goodbye To The XOMA Royalty PFDs
Seeking Alpha · 05/25 12:00
Weekly Report: what happened at XOMAP last week (0518-0522)?
Weekly Report · 05/25 09:58
XOMA Royalty shareholders approve 2026 employee stock purchase plan with 500,000 shares
PUBT · 05/22 10:05
XOMA Royalty amends Ligand merger deal to add HoldCo as party
PUBT · 05/18 13:12
Weekly Report: what happened at XOMAP last week (0511-0515)?
Weekly Report · 05/18 09:58
XOMA Q1 net income falls to $4.5 million; total income and revenues slip to $12.32 million
PUBT · 05/12 20:16
Weekly Report: what happened at XOMAP last week (0504-0508)?
Weekly Report · 05/11 09:56
Weekly Report: what happened at XOMAP last week (0427-0501)?
Weekly Report · 05/04 09:55
Deals of the day-Mergers and acquisitions
Reuters · 04/27 18:05
Ligand Pharmaceuticals to buy XOMA Royalty for USD 39 per share cash
PUBT · 04/27 12:17
Ligand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 million
Reuters · 04/27 12:06
XOMA ROYALTY CORP - LIGAND RAISES 2026 ADJ EPS GUIDANCE TO $8.50-$9.50; EXPECTS $1.50 ACCRETION TO ADJ EPS IN 2027
Reuters · 04/27 11:00
More
Webull provides a variety of real-time XOMAP stock news. You can receive the latest news about XOMA Royalty Corporation through multiple platforms. This information may help you make smarter investment decisions.
About XOMAP
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.